Sanofi helps Science 37 raise $31M to ‘reimagine’ clinical trials

The company is hoping to bring trials into patients' homes and out of central sites.

LA-based clinical research company Science 37 has raised $31 million in a Series B round as it looks to “expand clinical trial access to anyone, anywhere, anytime.”

The Series B was led by Redmile Group (whose MD Rob Faulkner will also join the firm as a board member), with further funding from Series A lead investors Lux Capital and dRx Capital, as well as investment from Sanofi Genzyme BioVentures.

Sanofi ($SNY) is also doing more than just stumping up cash, as it will give Science 37 “technical and strategic guidance through interactions with their international development teams and their affiliates working in the clinical trial ecosystem.”

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

The essence of what Science 37 does is to bring clinical trials into people’s homes, decentralizing setup and promising to help decrease costs while also increasing recruitment, always a major problem in studies.

The company, which is mainly a tech-based outfit, says it supplants physical trial sites with a single “metasite” and brings what the sponsor needs for their trial into a patient’s home.

It’s made possible by a cloud-based mobile research platform called Network Oriented Research Assistant that connects investigators and patients over the trial period and also allows patients to keep their own doc.

“The clinical trial process represents significant cost and risk in the development cycle for new therapeutics and medical devices,” said incoming director Faulkner.

“Science 37 brings a revolutionary approach to the clinical trial process and our investment underscores our confidence in the company's ability to deliver faster and less expensive clinical trials.”


Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.